Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis

References

• Teoh JYC, Huang J, Ko WYK, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78(6):1–11. doi: 10.1016/j.eururo.2020.09.006.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60(4):244–272. doi: 10.3322/caac.20077.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi: 10.1016/j.eururo.2020.03.055.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–792. doi: 10.1016/j.eururo.2013.11.046.
   PubMed Web of Science ®Google Scholar
• Abol-Enein H, Bono AV, Boyer M, et al. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–1934.
   PubMed Web of Science ®Google Scholar
• Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708–715. doi: 10.1634/theoncologist.2015-0440.
   PubMed Web of Science ®Google Scholar
• Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015;67(2):241–249. doi: 10.1016/j.eururo.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077. doi: 10.1200/JCO.2000.18.17.3068.
   PubMed Web of Science ®Google Scholar
• Ruiz de Porras V, Pardo JC, Etxaniz O, et al. Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions. Crit Rev Oncol Hematol. 2022;178:103795. doi: 10.1016/j.critrevonc.2022.103795.
   PubMed Web of Science ®Google Scholar
• Zargar-Shoshtari K, Zargar H, Dinney CP, et al. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World J Urol. 2016;34(5):695–701. doi: 10.1007/s00345-015-1667-4.
   PubMed Web of Science ®Google Scholar
• Blanco-Martinez E, Patel HD, Patel SH, et al. Deviations in cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer and implications for pathologic response and survival. J Urol. 2021;206(Supplement 3):e764–e765. doi: 10.1097/JU.0000000000002062.11.
   Google Scholar
• Aydin AM, Cheriyan SK, Reich R, et al. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022;40(10):453.e19–453.e26. doi: 10.1016/j.urolonc.2022.05.023.
   PubMed Web of Science ®Google Scholar
• D’Andrea D, Black PC, Zargar H, et al. Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer. J Urol. 2022;207(1):70–76. doi: 10.1097/JU.0000000000002190.
   PubMed Web of Science ®Google Scholar
• Ferro M, de Cobelli O, Musi G, et al. Three vs. Four cycles of neoadjuvant chemotherapy for localized muscle invasive bladder cancer undergoing radical cystectomy: a retrospective multi-institutional analysis. Front Oncol. 2021;11:651745. doi: 10.3389/fonc.2021.651745.
   PubMedGoogle Scholar
• Holmsten K, Omland LH, Als AB, et al. Implications for efficacy and safety of total dose and dose-intensity of neoadjuvant gemcitabine-cisplatin in muscle-invasive bladder cancer: three-week versus four-week regimen. BLC. 2022;8(1):71–80. doi: 10.3233/BLC-211556.
   Google Scholar
• Patel HD, Patel SH, Blanco-Martinez E, et al. Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival. J Urol. 2022;207(1):77–85. doi: 10.1097/JU.0000000000002189.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med. 2009;6(7):e1000100. doi: 10.1371/journal.pmed.1000100.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J National Cancer Inst. 1959;22:719–748.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2.
   PubMedGoogle Scholar
• Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235–243. doi: 10.2188/jea.15.235.
   PubMed Web of Science ®Google Scholar
• Hato SV, Khong A, de Vries IJ, et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831–2837. doi: 10.1158/1078-0432.CCR-13-3141.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238. doi: 10.1016/j.eururo.2011.12.010.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350–357. doi: 10.1016/j.eururo.2013.06.049.
   PubMed Web of Science ®Google Scholar
• Anceschi U, Brassetti A, Tuderti G, et al. Impact of clinical response to neoadjuvant chemotherapy in the era of robot assisted radical cystectomy: results of a single-center experience. J Clin Med. 2020;9(9):9.
   Web of Science ®Google Scholar
• Liu P, Fan B, Othmane B, et al. m(6)A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. Theranostics. 2022;12(14):6291–6307. doi: 10.7150/thno.71456.
   PubMed Web of Science ®Google Scholar
• Pfister C, Gravis G, Fléchon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses[formula presented. Eur Urol. 2021;79(2):214–221. doi: 10.1016/j.eururo.2020.08.024.
   PubMed Web of Science ®Google Scholar
• Pfister C, Gravis G, Fléchon A, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013–2022. doi: 10.1200/JCO.21.02051.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Tangen C, Daneshmand S, et al. SWOG S1314: a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. J Clin Oncol. 2022;40(6_suppl):536–536. doi: 10.1200/JCO.2022.40.6_suppl.536.
   Web of Science ®Google Scholar
• Flaig TW, Tangen CM, Daneshmand S, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27(9):2435–2441. doi: 10.1158/1078-0432.CCR-20-2409.
   PubMed Web of Science ®Google Scholar
• Sonpavde GP, Mariani L, Lo Vullo S, et al. Impact of the number of cycles of platinum based first line chemotherapy for advanced urothelial carcinoma. J Urol. 2018;200(6):1207–1214. doi: 10.1016/j.juro.2018.07.035.
   PubMed Web of Science ®Google Scholar
• Kato M, Kobayashi T, Matsui Y, et al. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol. 2021;28(12):1261–1267. doi: 10.1111/iju.14686.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–2177. doi: 10.1200/JCO.2010.32.3139.
   PubMed Web of Science ®Google Scholar
• Song Y, Qin C, Zhang C, et al. GNRH family genes contributed to gender-specific disparity of bladder cancer prognosis through exerting opposite regulatory roles between males and females. J Cancer Res Clin Oncol. 2023;149(10):6827–6840. doi: 10.1007/s00432-023-04640-2.
   PubMedGoogle Scholar
• Ikarashi D, Kitano S, Tsuyukubo T, et al. Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. Br J Cancer. 2022;126(4):606–614. doi: 10.1038/s41416-021-01628-y.
   PubMed Web of Science ®Google Scholar
• Luo H, Liu GL, Jian D, et al. Neoadjuvant chemotherapy improves the immunosuppressive microenvironment of bladder cancer and increases the sensitivity to immune checkpoint blockade. J Immunol Res. 2022;2022:9962397.
   PubMed Web of Science ®Google Scholar
• Hu J, Chen J, Ou Z, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med. 2022;3(11):100785. doi: 10.1016/j.xcrm.2022.100785.
   PubMedGoogle Scholar
• Li H, Chen J, Li Z, et al. S100A5 attenuates efficiency of anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma. Adv Sci. 2023;10:e2300110.
   Web of Science ®Google Scholar
• Cai Z, Chen J, Yu Z, et al. BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to anti-PD-1/PD-L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity. Adv Sci . 2023;10:e2207155.
   Web of Science ®Google Scholar
• Black AJ, Zargar H, Zargar-Shoshtari K, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020;38(1):3.e17-13–e27. doi: 10.1016/j.urolonc.2019.09.023.
   Web of Science ®Google Scholar
• Teo MY, Mota JM, Whiting KA, et al. Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma. Eur Urol. 2020;78(6):907–915. doi: 10.1016/j.eururo.2020.07.018.
   PubMed Web of Science ®Google Scholar
• Ecke TH, Voß PC, Schlomm T, et al. Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment. Int J Mol Sci. 2022;23(14):23. doi: 10.3390/ijms23147898.
   Web of Science ®Google Scholar
• Gil-Jimenez A, van Dorp J, Contreras-Sanz A, et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur Urol. 2023;83(4):313–317. doi: 10.1016/j.eururo.2022.07.023.
   PubMed Web of Science ®Google Scholar
• Vollmer T, Schlickeiser S, Amini L, et al. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Sci Transl Med. 2021;13(576):eabb3735. doi: 10.1126/scitranslmed.abb3735.
   PubMed Web of Science ®Google Scholar
• Rubino S, Kim Y, Zhou J, et al. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021;39(5):1539–1547. doi: 10.1007/s00345-020-03342-5.
   PubMed Web of Science ®Google Scholar
• Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81(5):523–532. doi: 10.1016/j.eururo.2021.10.035.
   PubMed Web of Science ®Google Scholar
• Hu J, Yu A, Othmane B, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11(7):3089–3108. doi: 10.7150/thno.53649.
   PubMed Web of Science ®Google Scholar